statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints

Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.
read more...

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a...

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31...

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntingtons Disease

Sage Therapeutics announced today topline results from the Phase 2 SURVEYOR Study. The study met its primary endpoint demonstrating a statistically significant difference as measured by the...

Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage...

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics

Latest Ratings for SAGE
 DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022Truist SecuritiesMaintainsHold Mar 2022MizuhoMaintainsNeutral
 View More Analyst Ratings for...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Volume	930,739.00
52-Wk High	$37.17
52-Wk Low	$9.73

SAGE Sage Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals